Paclitaxel Structural Formula (Paclitaxel 01)
Paclitaxel Injection, Solution
Product Images NDC 61703-342
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 61703-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Paclitaxel 01a
Figure 1. Survival: Cc Versus Tc (intergroup) (Paclitaxel 02)
Figure 2. Survival: Cc Versus Tc (gog-111) (Paclitaxel 03)
This is a statistical table presenting the proportion of survivors and related data. The table seems to contain information about a comparison between two groups (N 214, 196) with the number of events, hazard ratio, and number at risk indicated. There are also numbers representing the years, possibly indicating the time period observed.*
Figure 3. Disease-free Survival: Ac Versus Ac+t (Paclitaxel 04)
This appears to be a table related to the proportion of disease-free people treated with AC+T and AC in a medical study. It includes information on the number of events and the hazard ratio over a span of four years. It is not possible to determine the context or specifics of the study from this text.*
Figure 4. Survival: Ac Versus Ac+t (Paclitaxel 05)
This appears to be a table with information related to survival rates of individuals undergoing a specific treatment (AC+T) compared to a control treatment (AC) over a period of four years. The table includes information such as the number of individuals at risk, number of events (presumably deaths), and hazard ratio. However, without further context or information, it is difficult to understand the purpose or significance of this data.*
Figure 5. Disease-free Survival: Receptor Status Negative/unknown Ac Versus Ac+t (Paclitaxel 06)
The text is a table with data related to disease-free proportions. It includes different treatments or interventions (AC+T and AC) and their corresponding number of events, hazard ratio, and risk numbers. The table spans for up to 5 years.*
Figure 6. Disease-free Survival: Receptor Status Positive Ac Versus Ac+t (Paclitaxel 07)
This appears to be a section of a research or clinical trial report, documenting the proportion of disease-free individuals based on a given treatment regimen (AC+T) compared to a control group (AC). The table provides numerical values for the number of participants and the number of disease events observed, as well as the hazard ratio and confidence interval. The graph represents the proportion of disease-free individuals over a period of 4 years.*
Figure 7. Disease-free Survival: Premonopausal Ac Versus Ac+t (Paclitaxel 08)
This text appears to be statistical output from a medical or scientific study. It shows the proportion of participants in the study who are disease-free over a period of four years. The study included 966 individuals, and 201 of them experienced an event related to the disease in question. The results suggest that the use of AC+T treatment may have a slightly lower hazard ratio (HR) of 0.83, but the 95% confidence interval ranged from 0.67-1.01, indicating that the difference may not be statistically significant. The text also includes a table showing the number of participants at risk over the four-year period for different treatment groups.*
Figure 8. Disease-free Survival: Postmenopausal Ac Versus Ac+t (Paclitaxel 09)
This appears to be a chart or graph related to medical research. It shows proportions of people who were disease-free over a period of time. There are two groups represented, labeled as AC+T and AC. The numbers 04 and 02 may represent years or time intervals. The HR value of 0.73 suggests that the group labeled AC+T had a lower risk of disease compared to the AC group. The numbers in the "Number at Risk" column may indicate the number of participants in each group. Overall, the chart seems to be related to a study on a particular disease and the effectiveness of a treatment.*
Principal Display Panel (50 mL Vial Label)
Principal Display Panel (50 mL Vial Carton)
Paclitaxel 12
Paclitaxel 13
This appears to be a mix of diverse texts, including various numbers, symbols, and characters, which makes it challenging to generate a particular description. It seems that there are some medical-related terms present in the text, including Paclitaxel Injection, USP 30 mg/ 5 mL, which is a cytotoxic agent used in the treatment of different cancers. There is also a caution noted that dilution is required before intravenous infusion. However, the rest of the text appears to be a mix of random letters, numbers, and symbols, which cannot be used to provide further information. Therefore, the description would be: "Medical-related text including information about Paclitaxel Injection, USP."*
Paclitaxel 14
The text contains information about a drug called Paclitaxel Injection, USP, which is a cytotoxic agent that needs to be diluted before IV infusion. It is available in a multiple dose vial containing 100mg/16.7ml of the drug at a concentration of 6 mg/mL. The text also includes some illegible characters and symbols, and a few numbers that might be references to product codes or batch numbers.*
Paclitaxel 15
Paclitaxel Injection is a cytotoxic agent. Each mL contains 6 mg of Paditaxel, 527 mg of Polyoxy 35 Castor Oil, NF, 49.7% Dehydrated Alcohol USP, and 2 mg Citric Acid, USP. The usual dosage, directions, and precautions are included in the insert. Protect from light and store the vials at room temperature. Dilution is required before the intravenous infusion. The manufacturing details and 2D datamatrix are printed on the packaging. It is distributed by Hospira Inc., Lake Forest, IL 60045, USA. MADE IN CANADA. The barcode EAN 14 (GTIN 14) is included.*
Paclitaxel 16
Paclitaxel 17
This is a description of a medication called Paclitaxel, in the form of a 50 mLvial with 6 mg/mt dosage. It contains Polyaxyl, Castor O, Dehydrated Alcohol, and U Injection as its ingredients. A detailed dosage and usage instructions are available in the insert. Dilution is required before intravenous infusion. The lot number is s014321AA, and the bar code is EAN 14. The medication is distributed by Hospira Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
